Feature Editor's Introduction—Durable left ventricular assist device (LVAD) therapy has had
a remarkable evolution over the past 2 decades. Moving from a therapy once confined to …

The past five years have seen remarkable growth in the use of durable, continuous flow left
ventricular assist devices (LVAD) with associated improvements in mortality, quality of life …

The use of long-term left ventricular assist devices (LVADs) has revolutionized the treatment
of end-stage heart failure. The most significant advance in this field has been the longer …

Continuous-flow left ventricular assist devices (LVADs) have revolutionized advanced heart
failure care. These compact, fully implantable heart pumps are capable of providing …

Over the last half‐century, left ventricular assist device (LVAD) technology has progressed
from conceptual therapy for failed cardiopulmonary bypass weaning to an accepted …

NUMEROUS PUBLICATIONS each year report focused analyses of various aspects of the
continuously growing data set regarding patients supported by durable left ventricular assist …

Survival after implant of a left ventricular assist device (LVAD) continues to improve for
patients with end-stage heart failure. Meanwhile, more patients are implanted with a …

Continuous-flow (CF) left ventricular assist devices (LVADs) have become the standard of
care for patients with advanced heart failure refractory to optimal medical therapy. The goal …

The field of durable left ventricular assist devices has advanced dramatically since its
introduction into the clinical realm. From the first-generation pulsatile HeartMate XVE device …

Contemporary growth in the use of left ventricular assist devices (LVADs) to support patients
with advanced heart failure is remarkable. In the United States alone, more than 2,400 …